Weight Loss Medicine for Adults with Obesity
For adults with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with weight-related complications) who have failed lifestyle modifications, semaglutide 2.4 mg weekly should be prioritized as first-line pharmacotherapy due to its superior weight loss efficacy and mortality/cardiovascular benefits. 1
Recommended Pharmacologic Agents (in order of preference)
First-Line: GLP-1 Receptor Agonists
Semaglutide 2.4 mg subcutaneous weekly is the preferred agent given its magnitude of net benefit and should be prioritized over other anti-obesity medications for most patients 1. This agent:
- Achieves 15-20% mean weight loss 2, 3
- Reduces mortality and major adverse cardiovascular events (MACE) 2
- Provides glucoregulatory benefits (also approved for type 2 diabetes)
- Requires gradual dose titration to mitigate nausea/vomiting
- Carries increased risk of pancreatitis and gallbladder disease 1
Liraglutide 3.0 mg subcutaneous daily is the second-choice GLP-1 RA 1:
- Achieves 5-10% weight loss 3
- Similar glucoregulatory benefits and side effect profile to semaglutide
- Daily injection may be less convenient than weekly semaglutide
Second-Line: Combination Agents
Phentermine-topiramate ER (conditional recommendation, moderate evidence) 1:
- Preferentially use in patients with comorbid migraines (topiramate treats migraines)
- Avoid in cardiovascular disease and uncontrolled hypertension
- Topiramate is teratogenic—women of childbearing potential require consistent contraception
- Monitor blood pressure and heart rate periodically
Naltrexone-bupropion ER (conditional recommendation, moderate evidence) 1, 4:
- Consider for patients attempting smoking cessation or with depression
- Achieves 5.9-11.5% weight loss over 56 weeks 4
- Avoid in seizure disorders (lowers seizure threshold)
- Cannot use with opioid medications
- Monitor blood pressure/heart rate, especially first 12 weeks
- Cardiovascular safety not established (trial terminated early) 4
Third-Line: Monotherapy Options
Phentermine monotherapy (conditional recommendation, low evidence) 1:
- FDA-approved for short-term use (12 weeks), but often used off-label long-term
- Avoid in cardiovascular disease
- Monitor blood pressure and heart rate
Diethylpropion (conditional recommendation, low evidence) 1:
- Similar profile to phentermine
- Short-term FDA approval, often used off-label long-term
Not Recommended
Orlistat receives a conditional recommendation AGAINST use 1:
- Small weight loss benefit with significant GI adverse effects
- If used, requires daily multivitamin with fat-soluble vitamins (A, D, E, K) taken 2 hours apart from orlistat
Clinical Algorithm for Drug Selection
Start with semaglutide 2.4 mg weekly for most patients unless contraindicated 1
If semaglutide unavailable or not tolerated, use liraglutide 3.0 mg daily 1
If GLP-1 RAs contraindicated or patient prefers oral therapy:
Short-term bridging therapy → phentermine or diethylpropion monotherapy 1
Critical Implementation Points
General Principles
- All anti-obesity medications require chronic use—obesity is a chronic disease requiring long-term management 1
- Continue lifestyle interventions (diet, exercise, behavioral therapy) with all pharmacotherapy 1
- Selection should account for comorbidities, patient preferences, costs, and access 1
Common Pitfalls to Avoid
GLP-1 RAs (semaglutide, liraglutide):
- Delayed gastric emptying causes nausea/vomiting—use gradual dose titration 1
- Monitor for pancreatitis and gallbladder disease 1
Phentermine-topiramate ER:
- Pregnancy testing required—highly teratogenic 1
- Avoid in cardiovascular disease, uncontrolled hypertension, hyperthyroidism 1
- Risk of kidney stones with prolonged use; consider monitoring serum bicarbonate 1
- Take early in day to prevent insomnia 1
Naltrexone-bupropion ER:
- Screen for seizure history—contraindicated in seizure disorders 1, 4
- Cannot combine with opioids 1
- Avoid with fatty meals (increases drug levels) 4
- Dose adjustment needed for renal/hepatic impairment 4
Phentermine monotherapy:
- Monitor cardiovascular status—avoid in heart disease 1
- Controlled substance (schedule IV) with abuse potential 1
Special Populations
Type 2 diabetes: Semaglutide or liraglutide provide dual benefit for weight loss and glycemic control 1, 5
Cardiovascular disease: Semaglutide reduces MACE; avoid phentermine-containing agents 2
Obstructive sleep apnea: Liraglutide improves apnea-hypopnea index 5, 6
Renal impairment: Dose reduction required for naltrexone-bupropion ER; avoid in end-stage renal disease 4
Hepatic impairment: Dose reduction for naltrexone-bupropion ER; not recommended in severe hepatic impairment 4
Evidence Quality Note
The 2022 AGA guidelines 1 provide the strongest framework, with moderate-quality evidence supporting most recommendations. The 2026 systematic review 2 confirms semaglutide and tirzepatide (not yet widely available for obesity) show the most favorable results across outcomes including mortality reduction. The 2025 AACE consensus 4 and Canadian guidelines 7 align with prioritizing GLP-1 RAs as first-line therapy.